Vermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology & Diagnostics Forum

Nov 17, 2015, 09:00 ET from Vermillion, Inc.

AUSTIN, Texas, Nov. 17, 2015 /PRNewswire/ -- Vermillion, Inc. (NASDAQ: VRML), a bio-analytical solutions company focused on gynecologic disease, today announced that Valerie Palmieri, President and Chief Executive Officer of Vermillion, Inc., will present a corporate overview at the Canaccord Genuity Medical Technology & Diagnostics Forum.

Canaccord Genuity Medical Technology & Diagnostics Forum


Thursday, November 19, 2015


3:30pm Eastern Time


Westin Grand Central, New York


About Vermillion
Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in gynecologic disease. The company's lead diagnostics in the United States, OVA1®, and in the European Union, Overa®, are blood tests for pre-surgical assessment of ovarian tumors for malignancy, each using an innovative algorithmic approach. OVA1, which was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and Overa represent a new class of software-based diagnostics. For additional information, including published clinical trials, visit

Investor Relations Contact:
Michael Wood
LifeSci Advisors LLC
Tel 1-646-597-6983


SOURCE Vermillion, Inc.